Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
1. VALN reports strong immune response data for Lyme disease vaccine VLA15. 2. No safety concerns were raised after third booster doses in all age groups. 3. VLA15 is closest to approval; two Phase 3 trials nearing completion. 4. Estimated 476,000 annual Lyme disease cases in the U.S. highlight significant market need. 5. Pfizer plans BLA submission to FDA in 2026, potentially accelerating VALN's growth.